P100 RITUXIMAB-INDUCED COLITIS: THE MAYO CLINIC EXPERIENCE

  • Eckmann J
  • Chedid V
  • Quinn K
  • et al.
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Rituximab (RTX), an anti-CD20 monoclonal antibody used in treatment of hematologic and rheumatologic disease, depletes systemic and intestinal B-cells. Diarrhea is seen in w15% of people. Case reports associated RTX with de novo inflammatory bowel disease (IBD). We aim to characterize clinical features and course of RTX-induced colitis. METHOD(S): A retrospective cohort study of all patients with new-onset diarrhea after RTX at Mayo Clinic from 01/ 2006 to 06/2017. Those with diarrhea, concurrent/recent use of RTX in past year, and colon biopsy were included. Diagnosis of IBD or microscopic colitis (MC) before RTX or age<18 were excluded. Demographics, indication of RTX, colitis type and other variables were summarized as median and interquartile range (IQR) or percentage and proportions. Data was analyzed using JMP. RESULT(S): 460 patients (57% female, median age 57 years [IQR 43-68]) with RTX, diarrhea, and histology were evaluated. Of these, 23 (73.9% female, median age 63 years [IQR 38-72]) were identified RTX-induced colitis (Table 1): 60.8% IBD(8/23 CD, 6/23 UC) and 39.2%MC. Median daily bowel movements was 5 [IQR 3-14]. Most common symptoms along diarrhea were abdominal pain (65.2%) and weight loss (56.5%). Median time from first RTX dose to diarrhea was 20.3 months [IQR 11.3-76.5]. CD19 depletion was noted in all 11 who were tested at time of GI evaluation. Median of 3 months [IQR 4.6-25.2] diarrhea prior to initial GI evaluation. Among those with IBD, 85.7% (12/14) received IBD-directed therapy: 2 biologic monotherapy, 3 immunomodulators, 2 combo (biologic and immunomodulator), 3 5-ASA, and 2 budesonide. 2 required IBD-related surgery. RTX was stopped in 22/23 after diagnosis of RTX-induced colitis with complete improvement in symptoms in 13/22. CONCLUSION(S): RTX-induced colitis is rare but clinically significant. In our cohort, 5% with new onset diarrhea after RTX who underwent endoscopic evaluation had colitis. Diarrhea resolved in 60% after stopping RTX. (Table Presented).

Cite

CITATION STYLE

APA

Eckmann, J. D., Chedid, V., Quinn, K. P., Tse, C. S., Bonthu, N., Nehra, V., & Raffals, L. E. (2018). P100 RITUXIMAB-INDUCED COLITIS: THE MAYO CLINIC EXPERIENCE. Inflammatory Bowel Diseases, 24(suppl_1), S35–S35. https://doi.org/10.1093/ibd/izy019.112

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free